On Monday, shares of Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB), remained flat and shut at $0.780 inside the end purchasing and offering session. The last exchanging scope of the stock ranges amongst $0.76 and $0.79. Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company offers Lymphoseek, a receptor-targeted small-molecule radiopharmaceutical used in the evaluation of lymphatic basins that may have cancer involvement in patients; and Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its neurological development programs include NAV4694, an Fluorine-18 labeled positron emission tomography imaging agent, which is used as an aid the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment; and NAV5001, an Iodine-123 labeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinsons disease and other movement disorders with potential use as a diagnostic aid in dementia. Navidea Biopharmaceuticals, Inc. has research and development agreements with University of California.
Shares of Agilent Technologies Inc (NYSE:A), subtract -0.16% and shut at $44.97 inside the last exchanging session. The rest of the purchasing and offering scope of the stock levels among $44.65 and $45.24. The association’s commercial center capitalization is $14.30 Billion with the general uncommon loads of 324.00 million. Agilent Technologies Inc. (NYSE:A) recently declared that its board of directors has raised the company’s quarterly dividend to 13.2 cents per share of common stock. The dividend will be paid on Jan. 25, to all shareholders of record as of the close of business on Jan. 3.
The timing and amounts of future dividends are subject to determination and approval by Agilent’s board.